摘要
目的探讨个体化护理干预对住院精神分裂症患者生活质量的影响。方法随机选择符合ICD－10精神分裂症诊断标准的住院患者140例，分为研究组和对照组，各70例，均接受医生制订的医疗方案，包括抗精神病药物治疗和常规专科护理，研究组实施24周个体化护理干预，共随访72周。在入组时和入组4，12，36，48，60，72个月后测评两组患者的生活质量量表（SQLS）、住院精神患者社会功能评定量表（SSPI）及阳性和阴性症状量袁（PANSS）分值。结果入组前两组SQLS，SSPI和PANSS得分均无显著差异（P〉0．05）。入组12周后研究组S9LS和PANSS得分较对照组明显降低（P〈0．05），SSPl得分较对照组明显升高（P〈0．05）。研究组干预前后SQLS、SSPI和PANSS得分均有显著差异（P〈0．05或P〈0．01），对照组观察前后比较，SQKS总分无显著差异，SSPI总分有显著差异（P〈0．01），PANSS总分无显著差异；阳性症状、一般病理表现及阴性症状较观察后有显著差异（P〈0．05或P〈0．01）。结论在合理应用抗精神病药物基础上，对患者实施个体化护理干预能提高患者的社会技能，有效改善患者的生活质量，积极促进患者康复的作用。
Objective To investigate effect of individual nursing？on quality of life in inpatients with schizophrenia.Methods 140 schizophrenia inpatients fulfilling ICD-10 were randomly divided into study group（70 cases） and control group（70 cases）.all patients received the antipsychotics treatment and routine psychiatric nursing, the patients in study group were given individual nursing in 24 weeks based on it. all of them were followed up in 72 weeks, the patients were assessed by using the Schizophrenia Quality of Life Scale（SQLS）,Scale of Social function for Psychosis Inpatients（SSPI） and Positive and Negative Symptom Scale （PANSS） at baseline,4,12,36,48,60 and 72 weeks.Results The statistical differences showed no significance in the comparison of each factor scores and their total scores of SQLS,SSPI and PANSS between two groups before intervention （P〉 0.05）.after 12 weeks,the SQLS and PANSS scores was significantly lower（P〈0.05）,the SSPI scores were significantly higher（P〈 0.05） in study group than in control group.the scores of SQLS,SSPI and PANSS between before and after intervention were significantly differences in study group （P〈 0.05 or P〈 0.01）.in control group,the total scores of SQLS and PANSS were no significant differences between before and after intervention, the total scores of SSPI and the scores of positive,general psychopathology,negative in PANSS were significantly differences between before and after intervention.Conclusion With the antipsychoties treatment ,individ- ual nursing could be improving social function and quality of life in patients.
出处
《中国药业》
CAS
2015年第B12期254-257,共4页
China Pharmaceuticals
基金
上海市浦东新区科技发展基金创新资金项目,项目编号：PKJ2012-Y31.
